Novo Nordisk's (NOVOB DC) CagriSema 2.4 did not meet the primary endpoint of showing non-inferiority on weight loss vs tirzepatide 15mg at 84 weeks

• CagriSema achieved 23% weight loss after 84 weeks of treatment, tirzepatide achieved 25.5%.
• CagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks.
• Additional trials are exploring the full weight loss potential of CagriSema, including higher-dose combinations.

Novo Nordisk's CagriSema trial results indicate a miss on its primary endpoint compared to tirzepatide, revealing a smaller weight loss effect. This could impact investor sentiment, as the effectiveness relative to competitors is crucial for market positioning. The ongoing trials for higher doses suggest the company may still have avenues to enhance CagriSema's profile, but immediate market reactions may lean negative.